Contoso

Pharmaceuticals

BPOC

Notar Victor, gr.26

1. Ce este BPOC?
Boala pulmonară obstructivă cronică
(BPOC) se caracterizează prin limitarea
persistentă și progresivă a fluxului de
aer, printr-un răspuns inflamator cronic
la particulele nocive sau gaze. 
Limitarea cronică a fluxului respirator
este cauzată de o combinație de mici
leziuni respiratorii (bronșiolită
obstructivă) și distrucții
parenchimatoase (emfizem), în
combinație ce variază de la bolnav la
bolnav.
Contoso
Pharmaceuticals

page 2
 Expunere la fum de
Polimorfism genetic
tigara si substante
TGF-b1/ deficit de a1AT
toxice volatile

Citokinele si
proteazele Apoptoza, Scaderea
determina necroza sintezei
degradarea MEC matricei
Contoso
Distrugerea parenchimului pulmonar Pharmaceuticals

page 3
1. Ce este BPOC?

Inflamația cronică cauzează modificări

structurale și îngustarea căilor
respiratorii distale. Distrugerea
parenchimului prin procese inflamatorii
duce la pierderea simultană a alveolelor,
astfel scăzând reculul elastic al
plămânului.

Contoso
Pharmaceuticals

page 4
 Mecanisme
Expunerea repetata la substante toxice
fiziopatologice in
determina o inflamatie cronica la nivelul
plamanilor. patogeneza BPOC
Astfel, apare un infiltrat inflamator format din
neutrofile, macrofage si limfocite. Celulele
secreta citokine, elastaze si oxidanti,
contribuind la stresul oxidativ care distruge
MEC prin proteoliza. Produsii de degradare ai
elastinei contribuie la cronicizare.

In functie de raspunsul organismului la

agresiune, putem avea o distructie tisulara fara
fibroza ( emfizem ) sau fibroza interstitiala .
Studii recente arata ca principalul factor care
influenteaza evolutia bolii este raspunsul
celulelor mezenchimale.

Contoso
Pharmaceuticals

page 5
 Factori de risc in aparitia si evolutia
BPOC
Add Add Add Add Add
Picture Picture Picture Picture Picture

raspunsul Varsta
Deficit Expunere la Fumat celulelor
congenital de a-1 poluanti, mezenchimale la
antitripsina combustibili, agresiuni
subst toxice

Etiam aliquet eu mi Integer convallis Reparatia inadecvata Ut congue quis tortor

80% din acesti
pacienti dezvolta
quis lacinia. Ut suscipit ante eu a testului pulmonar in varius eget sodales. Contoso
fermentum a magna varius. Morbi a purus urma leziunilor Pharmaceuticals
emfizem pulmonar ut eleifend. dolor.
page 6
 Prioritize Authorize Monetize Tratament BPOC
Lorem ipsum dolor sit Etiam aliquet eu mi Integer convallis
amet, consectetur
adipiscing elit.
quis lacinia. suscipit ante eu
varius.
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Etiam aliquet eu mi quis.
Contoso
Pharmaceuticals

page 7
 Unique First to Market
Lorem ipsum dolor sit Etiam aliquet eu mi.
amet, consectetur Ut fermentum a
adipiscing elit. magna ut eleifend.

Product
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Tested Authentic Etiam aliquet eu mi quis.
Integer convallis Suspendisse sit amet
suscipit eu varius.
Morbi a purus dolor.
ipsum varius finibus
justo viverra blandit.
Contoso
Pharmaceuticals

page 8
Investigatii clinice
pentru diagnostic
BPOC

Contoso
Pharmaceuticals

page 9
 Section Divider
Lorem ipsum dolor sit amet, Contoso
consectetur adipiscing elit Pharmaceuticals

page 10
Business Model
Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Research Finance Invest

Lorem ipsum dolor sit Etiam aliquet eu mi Integer convallis
amet, consectetur quis lacinia. Ut suscipit ante eu
adipiscing elit. fermentum a magna varius. Morbi a purus
ut eleifend. dolor.

Contoso
Pharmaceuticals

page 11
Market Opportunity Option 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit.

$1B
• Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
• Etiam aliquet eu mi quis
lacinia. Ut fermentum a
magna ut eleifend. Integer
convallis suscipit ante eu
varius.
• Morbi a purus dolor.
Suspendisse sit amet ipsum
finibus justo viverra blandit.
$2B
• Ut congue quis tortor eget
sodales. Nulla a erat eget
nunc hendrerit ultrices eu nec
nulla.
• Donec viverra leo aliquet,
auctor quam id, convallis orci.
Contoso
Pharmaceuticals

page 12
Market Opportunity Option 2
Integer convallis suscipit ante eu varius. Morbi a purus dolor.

$3B
Opportunity to Build
$2B
Freedom to Invent
$1B
Few Competitors

Lorem ipsum dolor sit Etiam aliquet eu mi quis Integer convallis suscipit
amet, consectetur lacinia. Ut fermentum a ante eu varius. Morbi a
adipiscing elit. magna ut eleifend. purus dolor.

Contoso
Pharmaceuticals

page 13
Competition Option 1

Contoso Pharmaceuticals Competitor

• Nulla a erat eget nunc hendrerit ultrices eu nec
nulla. Donec viverra leo aliquet, auctor quam id,
convallis orci.
• Sed in molestie est. Cras ornare turpis at ligula
posuere, sit amet accumsan neque lobortis.
• Maecenas mattis risus ligula, sed ullamcorper nunc
efficitur sed.
Praesent venenatis quam tortor, id
viverra nunc rutrum a.
• Maecenas malesuada ultricies sapien sit amet
pharetra.
• Nunc tempus, risus sodales hendrerit, arcu dolor
commodo libero, a sollicitudin quam nulla quis
lectus. In at porta mauris.

Contoso
Pharmaceuticals

page 14
Competition Option 2
Convenience

Contoso
Pharmaceuticals

Expensive Affordable

Inconvenient Contoso
Pharmaceuticals

page 15
Growth Strategy
How will we scale in the future
Phase 1
Month, Year
• Lorem ipsum dolor sit
amet, consectetur
adipiscing elit.
• Etiam aliquet eu mi quis
lacinia. Ut fermentum a
magna ut eleifend.
Integer convallis suscipit
ante eu varius.
Phase 2 Phase 3
Month, Year Month, Year
• Morbi a purus dolor. • Donec viverra leo
Suspendisse sit amet aliquet, auctor quam id,
ipsum finibus justo convallis orci.
viverra blandit.
• Lorem ipsum dolor sit
• Ut congue quis tortor amet, consectetur
eget sodales. Nulla a erat adipiscing elit.
eget nunc hendrerit
ultrices eu nec nulla.
Contoso
Pharmaceuticals
page 16
Traction
Forecasting for success

Vendors Users Gross Company

Revenue Revenue Gross Revenue
$300,000

20YY 0 0 $0 $0
$250,000

20YY 10 100 $6,750 $1,013 $200,000

$150,000
20YY 50 500 $33,750 $5,063

$100,000
20YY 200 2000 $135,000 $20,250
$50,000

20YY 400 4000 $270,000 $40,500 $0

1 2 3 4 5 Contoso
Pharmaceuticals

page 17
Timeline
Our two-year action plan

Trials Marketing Launch

Month, 20YY Month, 20YY Month, 20YY

AUG SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR APR MAY

20YY 20YY

Legislation Investment Procurement

Month, 20YY Month, 20YY Month, 20YY

Contoso
Pharmaceuticals

page 18
Financials
Year 1 Year 2 Year 3
Detailers 5,000 40,000 160,000
Users 50,000 400,000 1 600,000
Sales 500,000 4 000,000 16 000,000
Average Price per Sale 75 80 90
Revenue @ 15% 5 625,000 48 000,000 216 000,000
• Cost of Revenue 0 0 0
Gross Profit 5 625,000 48 000,000 216 000,000
Expenses
• Sales & Marketing 5 062,500 38 400,000 151 200,000 70%
• Customer Service 1 687,500 9 600,000 21 600,000 10%

• Product
Development 562,500 2 400,000 10 800,000 5%
• Research 281,250 2 400,000 4 320,000 2%
Total Expenses 7 593,750 52 800,000 187 920,000
Contoso
EBIT -1 968,750 -4 800,000 28 080,000 13% Pharmaceuticals

page 19
Team

Mirjam Nils Victoria Lindqvist Angelica Astrom

COO COB CFO

Lorem ipsum dolor sit amet,
consectetur adipiscing elit. Etiam
aliquet eu mi quis lacinia. Ut
fermentum a magna ut eleifend.
Integer convallis suscipit ante eu
varius.
Morbi a purus dolor. Suspendisse sit
amet ipsum finibus justo viverra
blandit. Ut congue quis tortor eget
sodales. Nulla a erat eget nunc
hendrerit ultrices eu nec nulla.
Donec viverra leo aliquet, auctor quam
id, convallis orci. Sed in molestie est.
Cras ornare turpis at ligula posuere, sit
amet accumsan neque lobortis.

Contoso
Pharmaceuticals

page 20
Team Alternate

Mirjam Victoria Alexander

Nilsson Lindqvist Martensson
COO COB CFO

Angelica Mira Flora

Astrom Karlsson Berggren
Head of Operations Head of Technical Creative Director

Contoso
Pharmaceuticals

page 21
Funding

Fund Category Fund Category

Etiam aliquet eu mi quis lacinia.
Lorem ipsum dolor sit amet,
Ut fermentum a magna ut.
consectetur adipiscing elit. $14,000 $12,000

$32,000
$82,000

Fund Category Fund Category

. Integer convallis suscipit ante eu Suspendisse sit amet ipsum finibus
varius. Morbi a purus dolor. justo viverra blandit. Ut congue quis
tortor eget sodales. Contoso
Pharmaceuticals

page 22
• Lorem ipsum dolor sit amet, consectetur
adipiscing elit. Etiam aliquet eu mi quis
lacinia. Summary
• Ut fermentum a magna ut eleifend. Integer
convallis suscipit ante eu varius. Morbi a Summary tagline or
purus dolor. Suspendisse sit amet ipsum sub-headline
finibus justo viverra blandit.
• Ut congue quis tortor eget sodales. Nulla a
erat eget nunc hendrerit ultrices eu. Contoso
Pharmaceuticals

page 23
Thank You
April Hansson

+1 23 987 6554
april@contoso.com
Contoso
www.contoso.com Pharmaceuticals

page 24
Customize this Template

Template Editing
Instructions and Feedback

Contoso
Pharmaceuticals

page 25